Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Empagliflozin/Metformin FDC vs Single Tablets in Healthy Chinese Volunteers
NCT02102932Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity and Maximum Plasma Concentration. Started May 2014; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02102932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102932.